Lantheus Holdings Inc
$ 83.92
-0.02%
16 Apr - close price
- Market Cap 5,463,410,000 USD
- Current Price $ 83.92
- High / Low $ 84.30 / 82.44
- Stock P/E 24.61
- Book Value 16.87
- EPS 3.41
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.21 %
- 52 Week High 108.91
- 52 Week Low 47.25
About
Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. The company is headquartered in North Billerica, Massachusetts.
Analyst Target Price
$93.92
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-08-06 | 2025-04-30 | 2025-02-20 | 2024-11-06 | 2024-07-31 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 1.67 | 1.27 | 1.57 | 1.53 | 1.59 | 1.7 | 1.8 | 1.69 | 1.75 | 1.47 | 1.54 | 1.47 |
| Estimated EPS | 1.16 | 1.28 | 1.67 | 1.6539 | 1.5431 | 1.56 | 1.83 | 1.54 | 1.45 | 1.32 | 1.31 | 1.26 |
| Surprise | 0.51 | -0.01 | -0.1 | -0.1239 | 0.0469 | 0.14 | -0.03 | 0.15 | 0.3 | 0.15 | 0.23 | 0.21 |
| Surprise Percentage | 43.9655% | -0.7813% | -5.988% | -7.4914% | 3.0393% | 8.9744% | -1.6393% | 9.7403% | 20.6897% | 11.3636% | 17.5573% | 16.6667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LNTH
2026-04-15 15:10:22
Truist Financial has raised its price target for Lantheus (NASDAQ:LNTH) from $89.00 to $98.00, maintaining a "buy" rating and implying an 18.6% upside. This adjustment follows Lantheus's strong quarterly earnings, which surpassed expectations with $1.67 EPS and $406.8 million in revenue, and its positive FY2026 guidance. Analyst sentiment for the medical equipment provider remains largely favorable, with a "Moderate Buy" consensus rating.
2026-04-13 09:09:56
This article reports that Riley has reiterated its 'Buy' rating for Lantheus Holdings, Inc. (LNTH). However, the firm has adjusted its price target for LNTH downwards. The specific details of the new price target and the rationale behind the adjustment are not included in this snippet.
2026-04-11 05:50:00
This article analyzes Lantheus Holdings Inc. (NASDAQ: LNTH) using AI models to inform risk allocation. It highlights a potential shift in positive near-term sentiment, broader weak alignment, and elevated downside risk. The analysis provides specific trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis for LNTH.
2026-04-11 05:39:04
Lantheus Holdings (LNTH) has experienced recent share price fluctuations, with a 5.9% gain over the last week but a 21.0% decline over the past year. Despite these swings, the stock currently appears undervalued by over 50% according to a Discounted Cash Flow analysis, suggesting a fair value of $164.26 against its current price of $80.59. Various "Narrative" valuations, ranging from a bullish $91.38 to a cautious $76.00, also indicate potential undervaluation or slight overvaluation depending on future growth assumptions.
2026-04-11 00:10:14
This article analyzes Lantheus Holdings (LNTH) current valuation following recent share price volatility. Using a Discounted Cash Flow (DCF) model and Price-to-Earnings (P/E) ratio comparisons, the article suggests LNTH may be undervalued. It also presents "Bull" and "Bear" case narratives for the company, outlining different valuation scenarios based on varying growth assumptions.
2026-04-10 22:10:14
Lantheus Holdings Inc is a leader in radiopharmaceuticals, crucial for cancer diagnostics and other critical medical imaging in the U.S. The company benefits from high barriers to entry, recurring demand from hospitals, and a pipeline of new diagnostic and therapeutic agents, positioning it for durable growth. Investors are drawn to its specialized business model and focus on unmet needs within the growing U.S. healthcare sector, despite risks like supply chain vulnerabilities and competitive pressures.
